Halda raises $126M to advance 'hold and kill' solid tumor drugs into the clinic

The initial stages of oncology R&D aren’t short of intriguing new modalities, and Halda Therapeutics is planning to join them by using $126 million in fresh funding to bring its RIPTAC program into the clinic.